(Q36484912)

14 August 2017

1 reference

title

Aldosterone antagonists: effective add-on therapy for the treatment of resistant hypertension (English)

1 reference

14 August 2017

Krishna K Gaddam

1 reference

14 August 2017

Monique N Pratt-Ubunama

series ordinal

1 reference

14 August 2017

David A Calhoun

series ordinal

1 reference

14 August 2017

publication date

1 May 2006

1 reference

Expert Review of Cardiovascular Therapy

14 August 2017

published in

1 reference

14 August 2017

1 reference

14 August 2017

1 reference

14 August 2017

page(s)

353-359

1 reference

Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000.

14 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.3.353

Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.3.353

Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.3.353

Principal Results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.3.353

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.3.353

High prevalence of unrecognized sleep apnoea in drug-resistant hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.3.353

Hyperaldosteronism among black and white subjects with resistant hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.3.353

Screening for primary aldosteronism without discontinuing hypertensive medications: plasma aldosterone-renin ratio

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.3.353

Low-renin status in therapy-resistant hypertension: a clue to efficient treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.3.353

Prevalence of primary hyperaldosteronism in moderate to severe hypertension in the Central Europe region.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.3.353

Efficacy of low-dose spironolactone in subjects with resistant hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.3.353

Effect of nasal continuous positive airway pressure treatment on blood pressure in patients with obstructive sleep apnea

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.3.353

Refractory hypertension and sleep apnoea: effect of CPAP on blood pressure and baroreflex

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.3.353

Resistant hypertension revisited: a comparison of two university-based cohorts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.3.353

The role of spironolactone in the treatment of patients with refractory hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.3.353

Improvement in blood pressure with inhibition of the epithelial sodium channel in blacks with hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.3.353

Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.3.353

Efficacy of eplerenone versus enalapril as monotherapy in systemic hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.3.353

Efficacy and tolerability of eplerenone and losartan in hypertensive black and white patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.3.353

Efficacy of eplerenone added to renin-angiotensin blockade in hypertensive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.3.353

Aldosterone excretion among subjects with resistant hypertension and symptoms of sleep apnea

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.3.353

The current epidemic of primary aldosteronism: causes and consequences

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.3.353

High incidence of primary aldosteronism in 199 patients referred with hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.3.353

Evidence that primary aldosteronism may not be uncommon: 12% incidence among antihypertensive drug trial volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.3.353

The changing clinical spectrum of primary aldosteronism

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.3.353

Effects of diet and sodium intake on blood pressure: subgroup analysis of the DASH-sodium trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.3.353

21 January 2018

Identifiers

DOI

10.1586/14779072.4.3.353

1 reference

14 August 2017

1 reference